Literature DB >> 23435703

Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.

Rakhi P Naik1, Michael B Streiff, Sophie Lanzkron.   

Abstract

Venous thromboembolism (VTE) is common in patients with sickle cell disease (SCD). The etiology of increased risk of VTE in SCD patients is multifactorial and is related to both traditional factors and SCD-specific factors. Traditional risk factors such as central venous catheters, frequent hospitalization, orthopedic surgeries for avascular necrosis, and pregnancy may lead to increased incidence of VTE in the SCD population. In addition, SCD itself appears to be a hypercoagulable state, and many SCD-specific factors such as thrombophilic defects, genotype and splenectomy may modify the risk of VTE. SCD complications such as acute chest syndrome and pulmonary hypertension may also be related to VTE. Anticoagulation experts should be aware of these factors to help inform prophylaxis and treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23435703      PMCID: PMC4335704          DOI: 10.1007/s11239-013-0895-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  62 in total

Review 1.  Venous thromboembolism in cystic fibrosis.

Authors:  Clifford M Takemoto
Journal:  Pediatr Pulmonol       Date:  2011-10-17

2.  Delayed adverse vascular events after splenectomy in hereditary spherocytosis.

Authors:  R F Schilling; R E Gangnon; M I Traver
Journal:  J Thromb Haemost       Date:  2008-05-15       Impact factor: 5.824

3.  Reduced protein C levels--a contributory factor for stroke in sickle cell disease.

Authors:  U Khanduri; D Gravell; B S Christie; Z Al Lamki; M Zachariah; E Cherian
Journal:  Thromb Haemost       Date:  1998-04       Impact factor: 5.249

4.  Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia.

Authors:  M P Colella; E V De Paula; N Conran; J A Machado-Neto; J M Annicchino-Bizzacchi; F F Costa; S T O Saad; F Traina
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

Review 5.  Cathlink 20: a subcutaneous implanted central venous access device used in children with sickle cell disease on long-term erythrocytapheresis--a report of low complication rates.

Authors:  Ashok Raj; Salvatore Bertolone; Sheldon Bond; Diane Burnett; Audria Denker
Journal:  Pediatr Blood Cancer       Date:  2005-06-15       Impact factor: 3.167

Review 6.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

7.  Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

Authors:  Kenneth I Ataga; Charity G Moore; Cheryl A Hillery; Susan Jones; Herbert C Whinna; Dell Strayhorn; Cathy Sohier; Alan Hinderliter; Leslie V Parise; Eugene P Orringer
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

8.  Totally implantable intravenous catheters in the management of sickle cell anemia.

Authors:  G Phillips; C Slingluff; J Hartman; P Thomas; O Akwari
Journal:  Am J Hematol       Date:  1988-11       Impact factor: 10.047

Review 9.  Hypercoagulability in sickle cell disease: a curious paradox.

Authors:  Kenneth I Ataga; Eugene P Orringer
Journal:  Am J Med       Date:  2003-12-15       Impact factor: 4.965

10.  Clinical, hematological, and biochemical features of Hb SC disease.

Authors:  S K Ballas; C N Lewis; A M Noone; S H Krasnow; E Kamarulzaman; E R Burka
Journal:  Am J Hematol       Date:  1982-08       Impact factor: 10.047

View more
  30 in total

1.  Prospective study of sickle cell trait and venous thromboembolism incidence.

Authors:  A R Folsom; W Tang; N S Roetker; A V Kshirsagar; V K Derebail; P L Lutsey; R Naik; J S Pankow; M L Grove; S Basu; N S Key; M Cushman
Journal:  J Thromb Haemost       Date:  2014-12-11       Impact factor: 5.824

2.  Acute pain crisis in a patient with sickle cell disease undergoing ovarian simulation for fertility preservation prior to curative stem cell transplantation: case report and literature review.

Authors:  Michelle Matthews; Rebecca Pollack
Journal:  J Assist Reprod Genet       Date:  2017-08-11       Impact factor: 3.412

3.  Elevated D-dimer levels in African Americans with sickle cell trait.

Authors:  Rakhi P Naik; James G Wilson; Lynette Ekunwe; Stanford Mwasongwe; Qing Duan; Yun Li; Adolfo Correa; Alexander P Reiner
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

Review 4.  Imaging review of sickle cell disease for the emergency radiologist.

Authors:  Shenise N Gilyard; Scott L Hamlin; Jamlik-Omari Johnson; Keith D Herr
Journal:  Emerg Radiol       Date:  2020-07-31

5.  Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study.

Authors:  Riten Kumar; Joseph Stanek; Susan Creary; Amy Dunn; Sarah H O'Brien
Journal:  Blood Adv       Date:  2018-02-13

6.  Complications in pregnant women with sickle cell disease.

Authors:  Kim Smith-Whitley
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

7.  Hemoglobin to Hematocrit Ratio: The Strongest Predictor of Femoral Head Osteonecrosis in Children With Sickle Cell Disease.

Authors:  Douglas Worrall; Kim Smith-Whitley; Lawrence Wells
Journal:  J Pediatr Orthop       Date:  2016-03       Impact factor: 2.324

8.  Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.

Authors:  Megan Z Roberts; G Eric Gaskill; Julie Kanter-Washko; T Rogers Kyle; Brittany C Jones; Nicole M Bohm
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

9.  Evaluating the safety and effectiveness of venous thromboembolism prophylaxis in patients with sickle cell disease.

Authors:  Denise Kelley; Lauren Thornton Jones; Jun Wu; Nicole Bohm
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

Review 10.  Travelers with sickle cell disease.

Authors:  Shaina M Willen; Courtney D Thornburg; Paul M Lantos
Journal:  J Travel Med       Date:  2014-06-19       Impact factor: 8.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.